INTRODUCTION
Malignant brain tumors are among the most intractable problems in cancer. Glioblastoma (GBM), the most common and aggressive primary tumor, has a median survival of 16 months. Despite intense clinical efforts at targeting various signaling pathways, putative driver mutations, and angiogenesis mechanisms, no improvement in survival has emerged since 2005, with the addition of temozolomide to radiation as initial therapy (Cloughesy et al., 2014; Fine, 2014) . Brain metastases, similarly, are aggressive tumors that affect $200,000 patients per year in the United States (Lu-Emerson and Eichler, 2012) and usually occur late in the clinical course, often heralding end-stage disease. Treatment options are limited, and survival is measured in months (Owonikoko et al., 2014) . Although GBM and brain metastases represent a broad range of cancer subtypes with distinct cellular origins and diverse genetic programs, they exhibit common metabolic characteristics that may be the result of reprogramming to enable rapid growth in the brain. Using 13 C-NMR, we have previously shown in patients with GBM, lung, and breast cancer brain metastases that these tumors oxidize glucose in the citric acid cycle (CAC) to produce macromolecular precursors and energy (Maher et al., 2012) . The metabolic complexity of these tumors is further reflected in the identification of a ''bioenergetic substrate gap,'' whereby a significant fraction of the acetyl-CoA pool is not derived from blood-borne glucose (Maher et al., 2012) . The striking commonality of this finding among different grades of gliomas and metastatic tumors of diverse cellular origins prompted us to consider the possibility that an alternate or additional substrate(s) may serve as an important carbon source for generating CAC intermediates to support biosynthesis and bioenergetics in vivo.
Although the normal healthy adult brain relies almost exclusively on glucose as the major energy substrate, it can readily adapt to alternate fuels, including ketone bodies, short and medium chain fatty acids, and acetate (Ebert et al., 2003) . Astrocytes are capable of supporting neuronal function by utilizing acetate as a metabolic substrate under conditions of limiting glucose supply, including diabetic hypoglycemia and chronic alcohol abuse (Cloughesy et al., 2104; Schurr, 2001; Jiang et al., 2013) . Because GBMs develop from the astroglial lineage, we hypothesized that these tumors retain the capacity to metabolize acetate during transformation. The most common brain metastases, in contrast, arise from organs that are not known to utilize substrates other than glucose. We speculated, that the unique brain microenvironment might drive tumors of diverse origins to utilize the same metabolic substrates to fuel aggressive growth. To test this hypothesis in vivo, we used human orthotopic tumor (HOT) mouse models of GBM and brain metastases and applied methods in intermediary metabolism for studying multiple substrates using 13 C-labeled nutrients (Malloy et al., 1988; Sherry et al., 1992) . Coinfusion of 13 C-acetate and 13 C-glucose has been used extensively to study normal rodent brain metabolism in which differential handling of acetate and glucose by the glial and neuronal compartments can be demonstrated by 13 C-NMR of resected brain tissue. These methods enable direct tracing of the metabolic fate of infused substrates beyond simple uptake in the cell and therefore can be used to determine directly whether acetate can be oxidized by GBM and/or brain metastases in an orthotopic model in vivo.
Here, we report that mice harboring human GBM or brain metastases can completely oxidize acetate in the tumors. We have validated this finding in patient tumors by infusing 13 C-acetate in patients with GBM, breast cancer, and non-small cell lung cancer during surgical resection of their tumors and show that there is robust labeling of CAC intermediates by blood-borne 13 C-acetate.
In the article by Comerford et al. (2014) in this issue of Cell, the authors demonstrate a critical role for the nucleocytosolic acetylCoA synthetase enzyme, ACSS2, in hepatocellular carcinoma and broad immunoreactivity for ACSS2 in diverse human tumor types, including gliomas, breast cancer, and lung cancer. Here, we show that ACSS2 is upregulated in the HOT and primary human tumors, as well as a murine glioma model. In ACSS2 knockout mouse embryo fibroblasts (MEFs), 13 C-acetate fails to label CAC intermediates, and in human GBM neurospheres, stable ACSS2 knockdown leads to failure of self-renewal. These studies provide a potential mechanistic link between ACSS2 activity and in vivo acetate oxidation in tumors.
RESULTS

Glioblastomas Oxidize Acetate in the Citric Acid Cycle
The human orthotopic tumor (HOT) lines of GBM and brain metastases used in this study were each derived from an individual patient tumor, and implanted into the basal ganglia of NOD-SCID mice within 3 hr of surgical resection. All mouse experiments were approved by the Animal Resource Center, University of Texas Southwestern Medical Center (UTSW). Clinically symptomatic tumors arose within 2-4 months. The tumors, which are linked to UTSW Institutional Research Board (IRB)-approved collection of clinical information, were serially passaged and expanded in the mouse brain without adaptation to cell culture. Brain-only passaging helps ensure the preservation of the phenotypic, molecular and metabolic profiles of the human tumors and the tumor-stromal interactions, to the extent possible in an experimental system. We selected six HOT lines (UT-GBM1-6; Table S1 available online) that are representative of the most common GBM molecular profiles (Brennan et al., 2013) . Each line was generated at the time of the patient's initial diagnosis prior to any treatment and was studied here in early in vivo passage. A seventh HOT line (UT-GBM7), generated at the time of repeat surgery for tumor recurrence 15 months after initial resection in the same patient from which the UT-GBM6 HOT line was derived, was chosen to compare substrate utilization in the setting of recurrence and multimodality resistance. We have validated in vivo that UT-GBM6 is temozolomide (TMZ) sensitive, whereas UT-GBM7 is TMZ resistant (Sagiyama et al., 2014) . Representative histological sections from UT-GBM1 (Figure 1A) show an expansive mass (T) comprised of densely packed tumor cells and infiltration into the brain at the leading edges. In each mouse, the contralateral hemisphere served as a matched control for substrate utilization. It is referred to as ''non-tumor bearing brain'' (NT; Figure 1A ) rather than ''normal brain'' because the brain surrounding a large tumor is subjected to mass effect, an increase in reactive astrocytes and diffusible factors from the tumor and/or blood, conditions which could potentially impact brain metabolism.
13 C-NMR analysis of NT brain provides a valuable internal control for each mouse because the NT and T are exposed to the same circulating concentrations of 13 C-glucose and 13 C-acetate and systemic condition of the mouse. Thus, differences in labeling patterns and substrate utilization between NT and T reflect tumor-specific handling of the substrates. [1, [6] [7] [8] [9] [10] [11] [12] [13] C]glucose and [1,2-13 C]acetate were chosen for coinfusion because oxidation of each substrate produces distinct labeling patterns in CAC intermediates, enabling a direct comparison of substrate utilization in a given tissue (Malloy et al., 1988; Taylor et al., 1996; Deelchand et al., 2009 ). In the schema (Figure 1B) , metabolism of [1,6- 13 C]glucose (blue circles) leads to labeling of carbon 3 in pyruvate, followed by production of acetylCoA labeled in position 2, which condenses with oxaloacetate (OAA), leading to labeling of carbon 4 in a-ketoglutarate (a-KG), glutamate, and glutamine during the first turn of the CAC, and in carbons 3 and 4 with subsequent turns. This labeling generates a singlet (S) and doublet 3, 4 (D34) in glutamate C4 (GLU4) and glutamine C4 (GLN4) (for example, Figure 1C ). In contrast, metabolism of [1,2-13 C]acetate leads to labeling of both carbons (red circles) of acetyl-CoA with subsequent labeling of carbons 4 and 5 of a-KG and glutamate in the first turn of the CAC, generating a doublet 4,5 (D45) (for example, Figure 1C) . In subsequent turns of the cycle, labeling in carbons 3, 4, and 5 generates a doublet of doublets (quartet, Q) (for example, Figure 2A) . Thus, the 13 C-NMR multiplet pattern in carbon 4 of glutamate (GLU4) reflects differential labeling of the acetyl-CoA pool and provides a direct and unequivocal readout of substrate metabolism, whereby D45 and Q report acetate oxidation and S and D34 report glucose oxidation (Sherry et al., 1992) . The fractional amount of each multiplet in GLU4 can be obtained by determining the area of each multiplet relative to the total spectral area of GLU4, in which the areas of S, D34, D45, and Q sum to one (Marin-Valencia et al., 2012b) . The NT brain 13 C-NMR spectrum ( Figure 1C ) shows high signal to noise and well-resolved multiplets arising from 13 C-13 C coupling. Oxidation of both glucose and acetate in NT brain is demonstrated by the presence of S and D34 from glucose and D45 from acetate in GLU4 ( Figure 1C, inset) . Although the same multiplets are present in glutamine C4 (GLN4), the pattern of D45 and D34 is different from that in GLU4, recapitulating the well-recognized pattern that results from the differential handling of acetate and glucose in glia and neurons (Taylor et al., 1996) . The 13 C-NMR tumor spectrum from the same mouse (Figure 2A , inset) has several notable differences. First, there is a marked increase in D45 and the presence of Qs, indicating increased oxidation of acetate in the tumor when compared to the NT brain. Second, the similarity between the GLU4 and GLN4 labeling pattern (prominent D45 and small or absent D34) provides evidence that glutamine is being derived from glutamate in the tumor.
To determine the biological variability of acetate utilization within individual mice with tumors derived from the same parental line (UT-GBM1), we coinfused an additional four mice. brain and tumor spectra presented in Figures 2A and 2B (data not shown) . To quantify the relative contribution of each substrate to the labeling in GLU4, we calculated the acetate-to-glucose ratio, (D45+Q) to (S+D34). This has been used extensively in brain metabolism, where the differential labeling of multiplets enables discrimination of glial and neuronal metabolism, because astrocytes, but not neurons, are capable of oxidizing acetate (Deelchand et al., 2009; Marin-Valencia et al., 2012b) . In applying this analysis to brain tumors, we assume a single compartment comprised of tumor cells, based on histological analysis. Thus, the acetate-toglucose ratio in tumor GLU4 reflects the relative contribution of each labeled substrate. The ratio was calculated for the five mice, NT brain and tumor ( Figure 2B ).
In NT brain, glucose is the major substrate being oxidized with an acetate-to-glucose ratio of 15.8% ± 1.2% to 84.2% ± 1.1% (ratio 0.19 ± 0.02), achieved with 13 C-glucose fractional enrichment of 32% ± 5% in the blood and plasma acetate levels that rose approximately 4-fold (from 0.177 ± 0.02 mM to 0.619 ± 0.13 mM) during infusion. The acetate-to-glucose ratio is remarkably similar to that previously reported in normal adult mouse brain (calculated as 14% to 86%, ratio 0.16; Marin-Valencia et al., 2012b). The acetate-to-glucose ratio in the five tumors was 51.8% ± 2.9% to 48.3% ± 2.9% (ratio 1.02 ± 0.09), which was 5-fold higher than in NT brain (p < 0.001), demonstrating a significant shift toward acetate oxidation in the tumor.
Direct analysis of the multiplet ratios in GLU4 does not provide information about the contribution of unlabeled substrates in the acetyl-CoA pool, which could be playing an important role in fueling the tumor. To determine the size of the unlabeled pool, we applied a validated non-steady-state algorithm to the spectral analysis, which takes into account the total multiplet area in the glutamate C3 and C4 and the levels of infused substrates in the blood (Malloy et al., 1988 (Malloy et al., , 1990b . The fraction of acetylCoA due to acetate increased from 6.0% ± 1.2% in NT brain to 24.7% ± 2% in the tumor (p < 0.0001). This was associated with a decrease in the fractional contribution from glucose from 75.8% ± 3.7% in NT brain to 50.4% ± 9.1% in the tumor (p < 0.002), whereas the unlabeled fraction was not significantly different between NT brain (18.2% ± 4.0%) and tumor (25.5% ± 8.0%, p > 0.05). The decrease in glucose oxidation between NT brain and tumor may, at least in part, reflect a loss of the neuronal contribution to glucose utilization.
Having established the reproducibility of biological replicates in UT-GBM1 that has PDGFR overexpression/PTEN deletion, we next addressed the question of whether the ability to oxidize acetate is a function of the dominant oncogenes and/or tumor suppressor genes in the tumor. Mice from five additional GBM HOT lines (UT-GBM2-6; Table S1 ) were coinfused with [1,2-13 C]acetate and [1,6-13 C]glucose. The acetate-to-glucose ratios were calculated for these lines. No differences were found among the NT brains, and in each line, tumor acetate oxidation was higher than in NT brain. The relative 13 C-acetate contribution to GLU4 ranged from 18.8% to 52% (32% ± 5%) in the tumor. Differences in the percent acetate oxidation among the individual lines could not be attributed to amplification of EGFR or PDGFRa, presence of the EGFR VIII mutant, loss of PTEN, or loss of INK4a/ARF (data not shown).
Because all six GBM HOT lines were generated from patient tumors prior to the initiation of treatment, we next studied the tumor line generated from recurrent tumor (UT-GBM7) and compared it directly with the initial GBM HOT line from the same patient (UT-GBM6). Nearly identical labeling patterns in GLU4 and GLN4 were identified ( Figure S1 ), with dominance of the D45, an acetate-to-glucose ratio 25% to 75% in the initial tumor (UT-GBM6), and 27% to 73% in the recurrent tumor (UT-GBM7). The relative avidity for acetate and glucose is remarkably similar in these tumors that were derived independently more than a year apart and after extensive treatment and acquisition of chemo-and radioresistance.
Brain Metastases from Diverse Cell Types Oxidize Acetate To determine whether acetate oxidation is a feature of nonglial brain tumors, we studied five brain metastasis HOT tumor lines: breast cancer (estrogen receptor [ER] and progesterone receptor [PR] negative and HER2 positive), non-small cell lung cancer (no mutations in EGFR, ALK, or KRAS), clear cell renal cell carcinoma (VHLÀ/À), melanoma (BRAF V600E mutated), and endometrial cancer, a tumor which rarely metastasizes to the brain. There is a remarkable preservation of the signature histopathological and molecular features of the human brain metastases in the HOT models (see examples in Figure 3 ). Of note, the breast and lung cancer HOT lines were generated from the human tumors infused with 13 C-glucose during surgery that we reported previously (Maher et al., 2012) , each of which oxidized glucose but also showed a significant bioenergetic substrate gap. The study of these tumors here as orthotopic mouse models provided a unique opportunity to assess metabolic phenotype fidelity in these models. The 13 C-NMR spectral patterns from the five individual tumor lines and matching NT brains following coinfusion of [1,6-13 C] glucose and [1,2-13 C]acetate recapitulated the findings in GBM with remarkable similarity. Representative GLU4 and GLN4 labeling from the breast cancer ( Figure 3A ) and melanoma (B) Relative percent labeling of GLU4 by acetate and glucose in five replicates of NT brain and T from UT-GBM1. Peak areas in GLU4 were measured from the 13 C-NMR spectra. The contribution of 13 C-glucose (S+D34) (blue bars) and 13 C-acetate (D45+Q) (red bars) is expressed as a percent of the total peak area in GLU4. See also Figure S1 and Table S1 .
( Figure 3B ) reveal prominent D45 consistent with oxidation of acetate, as well as a large singlet (S) and small D34, consistent with glucose oxidation. The acetate-to-glucose ratio in GLU4 was calculated for NT brain and tumor. Similar to the GBMs, there was a significant increase in the fraction of acetate being oxidized in the tumors, ranging from 21 to 42% (29% ± 3%). Calculation of the fractional contribution to the acetyl-CoA pool for these tumors yielded 14.5% ± 3.9% from 13 C-acetate, 49.2% ± 5.6% from 13 C-glucose and 37% ± 4.3% from the unlabeled substrate.
Glutamine Is Not Directly Oxidized in the CAC of GBM and Brain Metastases In Vivo
We have previously shown that GBM HOT tumors do not oxidize glutamine in the CAC in vivo (Marin-Valencia et al., 2012c) . Here, we examined an additional two GBM HOT lines to increase the molecular diversity of the lines being examined See also Figure S2 and Table S1. and three brain metastasis HOT lines (non-small cell lung cancer, melanoma, and endometrial cancer) to determine whether glutamine could be directly oxidized in these tumors. Nearly identical spectra were obtained following infusion of [U-13 C]glutamine in the three tumor lines ( Figures 3C, S2A , and S2B) and in GBM (data not shown). GLN4 was dominated by large Qs, which is consistent with the presence of 13 C-glutamine in the tumor. The presence of smaller Qs in GLU4 suggests that there is some direct exchange of 13C-glutamine with glutamate. However, the GLU4 in each tumor was dominated by D45, a pattern that cannot be produced simply from exchange with glutamine. Moreover, prominent Qs in malate and aspartate were not visible in the spectra ( Figures 3C and S2 ), as would have been expected if [U- 13 C] glutamine had exchanged with glutamate, which then exchanged with a-KG and subsequently was fully oxidized in the CAC. An alternative route for GLU4 13 C labeling in the tumor was more likely than direct glutamine oxidation. The multiplet patterns in lactate and alanine from liver, NT brain, and tumor from the lung brain metastasis HOT line ( Figure S2B ) are consistent with production of 13 C-glucose from infused [U-
13 C]glutamine outside the CNS, likely in the liver, with subsequent 13 C-glucose oxidation in NT brain and tumor. This is supported by the presence of 13 C-labeled glucose in the liver 13 C-NMR spectrum ( Figure S2C ). Taken together, the labeling patterns in the HOT GBM and brain metastasis tumors following infusion of [U-13 C]glutamine further extends our previous finding in GBM that glutamine is taken up by the tumors but is not directly oxidized in the CAC in vivo.
ACSS2 Upregulation Is Associated with More
Aggressive Disease in Glioma ACSS2 is a critical enzyme for converting acetate to acetyl-CoA in murine models of liver cancer (Comerford et al., 2014) and was assessed here for a potential role in acetate metabolism in brain tumors. ACSS2 immunohistochemistry (IHC) showed moderate to high expression in 6 of 7 GBM and all brain metastasis HOT lines ( Figure S3 ). It was notable that the GBM with the lowest fractional acetate oxidation ($18%) had the lowest ACSS2 expression by IHC (histoscore = 50). ACSS2 expression in our clinically annotated glioma tissue microarray (TMA) was variable ( Figure 4A ) but significantly higher in GBM than the grade II and II gliomas ( Figure 4B ). Among the grade II and III gliomas, shorter survival time was associated with higher ACSS2 staining (Figure 4C) . ACSS1, ACSS3, sterol regulatory element binding protein (SREBP-1) expression in the TMA was not correlated with ACSS2 expression or with survival in any of the clinical subgroups (data not shown).
To determine whether ACSS2 has a direct impact on GBM growth, primary neurosphere cultures derived from two independent GBM HOT lines were infected with retroviruses expressing a small hairpin RNAi (shRNAi)-targeting ACSS2 for knockdown (KD) or a scrambled shRNAi (SCR) for control. Comerford et al. (2014) have extensively characterized these retroviruses. Infection with ACSS2-KD shRNAi, but not SCR, resulted in cell death ( Figure 5A ). Surviving GBM cells failed to form neurospheres (2% ± 0.5% versus 23% ± 4%, p < 0.001) and thus could not be assessed for in vivo tumorigenicity.
ACSS2 Expression Is Associated with Transformation and Enables
13
C-Acetate Incorporation into Glutamate Next, we investigated whether ACSS2 has a potential role in glioma tumorigenicity. Primary astrocyte cultures were generated from multiallele conditional mice carrying glioma-relevant muta-
, and LSL BRAF
V600E
) that activate the PI3K/ AKT and MAPK/ERK pathways. In this ex vivo model, successive accumulation of mutations was associated with increased ACSS2 expression, with the triple-mutant cells, p53
, having the highest expression ( Figure 5B ). High-grade gliomas generated from intracranial implantation of the triple-mutant cells were able to oxidize acetate when coinfused with 13 C-acetate and 13 C-glucose ( Figure 5C ). It is notable that, in contrast to the tumor suppressor-deficient, immortalized primary astrocytes, wild-type (WT) astrocytes markedly downregulated expression of all ACSS enzymes under standard culture conditions ( Figure 5D ), making it an unreliable experimental system for further in vitro acetate metabolic studies.
To determine whether there is a direct mechanistic link between ACSS2 and oxidation of 13 C-acetate, we investigated the extent of 13 C-acetate incorporation into glutamate in ACSS2 KO MEFs. The KO MEFs exhibited very little incorporation of 13 C-acetate into glutamate, whereas reintroduction of the WT ACSS2 gene into these cells significantly increased acetate incorporation into glutamate ( Figure S3 ). This direct genetic gain-of-function experiment provides a compelling link between ACSS2 and acetate oxidation in the CAC.
C-Acetate Is Oxidized in Patient Brain Tumors
To validate in humans the finding that acetate can be oxidized in the orthotopic models, we next infused [1,2-13 C]acetate in four patients (two GBM, one breast cancer brain metastasis, and one non-small cell lung cancer brain metastasis) during surgical resection of their tumors. Despite the diversity of tumor types, nearly identical 13 C-NMR spectra with excellent signal-to-noise ratio and robust labeling in glutamate and glutamine were obtained in the four tumors (Figures 6, 7, and S4) . The dominance * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * ** * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * of the D45 and presence of quartets (Q) in GLU4 and GLN4 is direct evidence that acetate was oxidized in the CAC. Moreover, the same multiplet pattern in glutamine demonstrates that this metabolite was generated from glutamate that had originated as blood-borne acetate.
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C-acetate enrichment in the blood was 88.5% ± 6.4%. Less than 3% (2.4% ± 1.1%) 13 C-glucose was recovered in the blood, demonstrating that the labeling in the tumors was not due to 13 C-glucose production outside the CNS. The fractional contribution of [1,2- 13 C]acetate to the acetyl-CoA pool in the four tumors was 47.8% ± 3.8%. Unlabeled substrate accounted for 51.3% ± 2.6% of the acetyl-CoA pool, with 1.7% ± 0.4% coming from [2-13 C]acetate, consistent with natural abundance 13 C. The unlabeled fraction is likely due in large part to circulating glucose, based on data from our previous study of brain tumor patients infused with 13 C-glucose (Maher et al., 2012) and the ability of the orthotopic mouse tumors to co-oxidize glucose and acetate. ACSS2 immunoreactivity ranged from moderately to strongly positive in the four tumors with specificity demonstrated in the lung brain metastasis (Figure 7) , where tumor, but not surrounding stroma, is labeled. 
DISCUSSION
Determining the carbon source(s) for biosynthesis and bioenergetics in rapidly proliferating tumors in vivo represents a critical step toward identifying potential vulnerabilities for therapeutic targeting. Our initial 13 C-NMR data from 13 C-glucose infusion in brain tumor patients (Maher et al., 2012) demonstrated a complex metabolic tumor phenotype that had not previously been reported; excess production of lactate (the Warburg effect) occurring simultaneously with CAC oxidation of glucose as well as oxidation of another unidentified substrate(s), termed the ''bioenergetic substrate gap.'' Here, we show that brain tumors from widely diverse cellular origins have the capacity to oxidize infused 13 C-acetate. This finding in GBMs is perhaps not surprising given that glial cells, the presumptive GBM cells of origin, are well known to be capable of oxidizing acetate. This suggests that, despite the extensive molecular reprogramming that is a hallmark of GBM, the ability to oxidize acetate is preserved, if not enhanced, in the tumors. 11 C-acetate positron emission tomography (PET) positivity has been reported in gliomas (Yamamoto et al., 2008) , consistent with our finding that acetate is actively taken up by the proliferating tumor cells. Nutrient uptake, however, although being of significant clinical utility as an imaging biomarker, provides no information about entry of the nutrient into specific metabolic pathways. A major advantage of 13 C-NMR, as demonstrated here, is that there are multiple internal controls within a single spectrum for examination of the relative activity of specific metabolic pathways. For example, the pyruvate pool is read out by labeling in lactate and alanine, whereas the acetyl-CoA pool is read out by labeling in glutamate.
The finding that brain metastases from a wide spectrum of cellular origins also oxidize acetate, however, was not anticipated because organs that most frequently give rise to tumors that metastasize to the brain (lung, breast, kidney, and melanoma) are not known to show significant 11 C-acetate uptake on PET.
The data suggest that the ability to oxidize acetate is either a unique adaptation to the brain microenvironment or a more general property of tumor cells. In support of the latter possibility, several non-CNS tumors, including hepatocellular and prostate cancer, show avid differential 11 C-acetate uptake on PET relative to the normal organ (Ho et al., 2003; Oyama et al., 2002) . ''Co-oxidation'' of acetate and glucose was seen in all of the GBM and brain metastasis HOT models, raising the possibility that substrate co-oxidation might be an adaptive mechanism Figure 2 . Chemical shift assignments are the same in Figure 7 : 1, alanine C3; 2, lactate C3; 3, NAA C6; 4, acetate C2; 5, unassigned; 6, glutamine C3; 7, glutamate C3; 8, unassigned; 9, glutamine C4; 10, glutamate C4; 12, NAA C3; 16, glutamine C2; 17, glutamate C2.
in rapidly proliferating tumors. It would ensure the availability of an adequate pool of carbons to generate CAC intermediates and support the high bioenergetic demands of growth while a large fraction of the glucose is being diverted to lactate. In this study there was no evidence of direct 13 C-glutamine oxidation in the orthotopic models, which may reflect differential substrate handling in brain tumors. Normal plasma acetate levels in nonfasted humans range between 0.05 mM (Tollinger et al., 1979) and 0.18 mM (Skutches et al., 1979) . Under normal resting conditions, circulating acetate levels may contribute up to 10%-15% of the basal energy demands of brain astrocytes (Dienel and Cruz, 2006) . Circulating free acetate is generated by fermentation of carbohydrates in the gut by commensal anaerobes and by the liver under ketogenic conditions (low glucose) as a final product of fatty acid oxidation or by ethanol metabolism in heavy drinkers (Jiang et al., 2013) . It has recently been reported that 3 hr after oral administration of 13 C-inulin to mice, doublets of C4 glutamate and glutamine can be clearly resolved in brain by high-resolution magic angle spinning MR spectroscopy from brain uptake of circulating 13 C-labeled acetate (Frost et al., 2014) . Moreover, the relative contribution of acetate to brain metabolism has been shown to increase following brain injury, which limits glucose oxidation (Bartnik-Olson et al., 2010) . This finding may be analogous to brain tumor regions with a paucity of active neurons and limited PDH activity as a result of intratumoral hypoxia. Taken together, there is clear evidence that normal circulating acetate levels may be adequate to contribute to the metabolic demands of the tumor. In order for the tumor cell to metabolize acetate, the cell must upregulate ACSS2, the enzyme critical for converting acetate to acetyl-CoA, as shown in hepatocellular carcinoma in the accompanying manuscript (Comerford et al., 2014) . The increased expression of ACSS2 in GBM when compared to the lower grade gliomas supports the assertion that upregulation of this enzyme is linked to an increase in acetate oxidation by the tumor. Higher expression of ACSS2 is associated with shorter survival among the patients with grade II and III gliomas, potentially identifying tumors that are destined to transform to grade IV (GBM) more rapidly.
GBM neurospheres have been shown to be critically dependent on oxidative phosphorylation, but not on inhibition of glycolysis (Janiszewska et al., 2012) . This finding is consistent with our observation that inhibition of ACSS2 in the GBM neurospheres results in loss of clonogenicity and cell death and supports the hypothesis that ACSS2 is important for supporting GBM viability. Moreover, the data from the genetically engineered glioma model show that mutations that drive AKT and ERK pathways (loss of PTEN and constitutive BRAF V600E activation) converge to increase ACSS2 expression ( Figure 5 ). The most direct link between the enzyme and the cell's ability to oxidize acetate in the CAC was shown in ACSS2 null MEFs. Although this is a different 13 C-NMR spectrum with GLU4, GLN4, and ASP3 insets. Abbreviations are the same as in Figure 2 . Chemical shift assignments are the same as in Figure 6 , with the following additions: 11, aspartate C3; 13, glycine C2; 14, alanine C2; 15, aspartate C2. See also Figure S4 for 13 C-spectra from two additional patient tumors.
system than glial cells, the finding that labeled glutamate from 13 C-acetate increased markedly in a time-dependent manner in ACSS2 null MEFS when the WT ACSS2 was reintroduced into the cells is consistent with the wide range of tumor cell types that are able to oxidize acetate. Recent evidence suggests that in order for tumor cells to adapt to the brain microenvironment, they must undergo unique genetic adaptations (Valiente et al., 2014) . In view of this formidable challenge, identification of a potentially druggable target, such as ACSS2, which appears to have little known function in normal cells, offers unique advantages in therapy development. The current work and that of Comerford et al. (2014) underscores the value of in vivo studies in cancer metabolism. Having orthotopic tumor models of both GBM and a wide range of brain metastases that have been vigorously cross-validated with human data will enable rapid in vivo workup of novel small-molecule inhibitors that target acetate metabolism, such as ACSS2. In addition, the feasibility of the 13 C-nutrient methodology in patients enables a host of follow-up questions to be addressed from this work, including whether the ability to oxidize acetate is a property of early-stage tumors or of the acquisition of metastatic potential. Rapid translation is a critical need for patients suffering from GBM and brain metastases, where prognosis is measured in months.
EXPERIMENTAL PROCEDURES
Generation of HOT Mouse Models of GBM and Brain Metastases
Generation of the HOT models of GBM and brain metastases have been previously described (Marin-Valencia et al., 2012a) . Briefly, tumor samples were obtained from patients at UTSW Medical Center at the time of craniotomy and tumor resection after written informed consent under an IRB-approved clinical protocol. All brain metabolic labeling experiments were performed in awake, alert mice following placement of an indwelling jugular venous catheter. For the isolation of tumor and NT brain regions, the whole brains were cut into 1 mm coronal sections. The sections were then microdissected to minimize contamination of tumor and NT regions.
Primary Cell Cultures
Primary astrocyte cultures were cultured as previously described (Bachoo et al., 2002) Isotope Laboratories) as a bolus of 0.3 mg/g of body weight for each tracer (in 0.3 ml of saline) infused over 1 min, followed by a continuous infusion of 0.0069 mg/g of body weight/min for each tracer (in 0.431 ml of saline) at 150 ml/hr for 150 min. For the experiments using glutamine, mice were infused with [U-
13
C] glutamine (95% enriched; Sigma-Aldrich Isotec) as a bolus of 0.28 mg/g of body weight for the tracer (in 0.3 ml of saline) infused over 1 min, followed by a continuous infusion of 0.005 mg/g of body weight/min (in 0.45 ml of saline) at 150 ml/hr for 180 min.
Human Studies
Patients were enrolled in a UTSW IRB-approved protocol to infuse 13 C-isotopes (glucose and acetate). For [1,2-13 C]acetate infusion, patients were dosed with 6 mg/kg/min for 5 min, followed by 3 mg/kg/min for 2-3 hr. Patient recruitment and consent, as well as blood and tumor sampling, have been previously described (Maher et al., 2012) .
C-NMR Spectroscopy
Proton-decoupled 13 C-spectra of tumor and NT brain extracts were acquired at 150 MHz for 13 C on Agilent VNMRS Direct Drive Console using 3 mm broadband NMR probe (Agilent Technologies). Various 13 C resonances were assigned based on chemical shift position referenced to the lactate C3 singlet at 20.8 ppm. Relative peak areas of the multiplets were obtained using ACD NMR Processor as previously described (Maher et al., 2012; Malloy et al., 1987 Malloy et al., , 1990a . RNA Isolation, cDNA Preparation, and Quantitative PCR RNA was isolated from cells in culture using an RNA Isolation Kit (QIAGEN RNeasy Mini Kit), following the manufacturer's protocol. cDNA was generated using the iScript cDNA Synthesis Kit (BioRad). Quantitative real-time PCR using iTaq SYBR Green Supermix with ROX (Bio-Rad) was performed on a StepOnePlus Real-Time PCR Systems (Applied Biosystems).
Molecular Analysis
DNA was prepared in accordance with standard methods, and quantitative PCR for EGFR, ALK, BRAF V600E, PTEN, p16, and p19 was done with standard primer sets for these genes.
Plasma Acetate Measurement
Plasma acetate was measured using standard manufacturer protocols (Biovision Colorimetric Assay Kit, cat# K658). Briefly, 1 ml of the diluted clear filtrate plasma was used for experimental samples. The reaction was performed at room temperature for 40 min, and an optical reading was taken at 450 nm using spectrophotometer. The unknown sample concentration was calculated from the standard curve.
Metabolite Extraction and Liquid Chromatography-Tandem Mass Spectrometry Cells were seeded on 6 cm plate to 70%-80% confluency. After two washes in PBS, cells were cultured with glutamine starvation medium (Dulbecco's modified Eagle's medium without glucose and glutamine [cat # D5030, SigmaAldrich], 3.7 g/l sodium bicarbonate, 5.9 g/l HEPES, 20 mM glucose, 10% FBS), 2 mM sodium [1,2-13 C]acetate (cat# CLM-440-1; Cambridge Isotope Laboratories) was added to the cells, and metabolites were extracted 0, 0.5, 1, 2 hr after acetate addition. After washing with ice-cold PBS, 500 ml of icecold 50% high-performance liquid chromatography-grade methanol was added to the cells. The plate was floated on liquid nitrogen immediately until the methanol was frozen. The plate was removed from the liquid nitrogen and scraped until the methanol was thawed. The suspension was then passed through ten freeze/thaw cycles using a bead beater and liquid nitrogen and then centrifuged at 16,000 g at 4 C for 10 min. Supernatants were transferred to a new tube and dried down. Metabolites were resuspended in 140 ml TBA buffer (5 mM tributylammonium acetate [pH 5.0]) and vortexed for 15 min. The solution was placed on ice for 30 min and then centrifuged at max speed for 5 min. The supernatants were transferred to a new tube, placed on ice for 30 min, and then centrifuged at max speed for 5 min. The supernatants were then processed for liquid chromatography-tandem mass spectrometry analysis as described previously using a water/methanol gradient with TBA as the ion pairing agent. (Tu et al., 2007) .
Retroviral Studies
ACSS2-shRNA-expressing retroviral plasmid with a puromycin selection gene was used for knockdown studies. We used a scrambled shRNA as control. Retroviral-containing media was obtained from transfected 293T cells and added to GBM cells, followed by puromycin selection.
Statistical Analysis
All pooled results are reported as mean ± SEM. For the evaluation of the acetate-to-glucose ratio between tumor and NT brain, a paired t test was used, and results are reported as mean ± SEM. For ACSS2 IHC evaluation, the immunostained TMA slides were scored manually by assigning to each core a value for ACSS2 staining intensity on a scale of 0-3 and a value representing the proportion of tumor cells staining on a scale of 0%-100%. These two values (intensity and percent positive cells) were then multiplied to obtain a histoscore (range, 0-300), which was used in further analyses. ACSS2 histoscores were dichotomized to high and low at the median. Kaplan-Meier survival curves were generated and compared with the Mantel-Cox (log rank) test using GraphPad Prism (v. 6.01) software (GraphPad).
For further details, please refer to the Extended Experimental Procedures. 
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